VE202 is an orally administered, investigational live biotherapeutic product consortium consisting of 16 strains of bacteria, rationally selected to induce immune tolerance in the gut, reverse gut microbiota abnormalities common in IBD, and strengthen the epithelial barrier.

Results describing the biology and candidate selection of VE202 were previously published in Nature nature.com/articles/natur… nature.com/articles/natur… and Amanda Prince will be presenting additional data at the Keystone Symposia “Mechanisms of Microbiota-Immune Interactions”

In a Phase 1 study in NHV, VE202 strains colonized robustly, in both a dose- and duration-dependent manner and accelerated conversion of 1o bile acids to immunomodulating 2o bile acids that protect against intestinal inflammation compared to PBO. VE202 was also well tolerated

COLLECTiVE202 collective202study.com is a double-blind, placebo-controlled, randomized clinical trial that is being conducted at sites in the US and EU. It is enrolling 100 patients with mild-to-moderate UC between the ages of 18 and 75 years.

Either VE202 or PBO is added to background therapy. All study participants will have an opportunity to receive VE202. 1o endpoints are safety and endoscopic response; 2o endpoints are clinical response and remission, among others

Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023 - businesswire.com/news/home/2023…

8 years (!) before diagnosis, elevated platelets are a signal of developing Crohn’s disease. Great work from Marie Vibeke Vestergaard Tine Jess PREDICT IBD Cell Reports Medicine cell.com/cell-reports-m…

There is only one thing harder to get from an investor than💰: candid feedback I wrote some thoughts here Timmerman Report 🧵 including rationalizations investors give themselves to avoid giving it & how entrepreneurs can improve odds of getting it /1 timmermanreport.com/2024/01/one-th…

Vedanta Biosciences team at FC Barcelona game during #ECCMID2024 !

Thank you CARB-X for the continued support of Vedanta Biosciences, Inc. antibacterial programs. This partnership helps advance VE707 into IND in preparation for a first-in-human study in prevention of MDRO infections. vedantabio.com/news-media/pre…

If you are attending #DDW2024 and interested in microbiome therapeutics check out Vedanta Biosciences Emily Crossette's presentation on VE303, a potential first-in-class Live Biotherapeutic Product for prevention of rCDI entering Phase 3 And if you want to catch up there, DM me.

We have enrolled the first patient in the pivotal Phase 3 study of VE303 for the prevention of recurrent C. difficile Infection. To our knowledge, this is the 1st registrational study of a Live Biotherapeutic Product for rCDI An important milestone in our field /1

FDA has approved two Fecal Microbiota Products for rCDI, which provide patients access to an alternative to unregulated FMT fda.gov/vaccines-blood… /2

Fecal Microbiota Products are made from donor feces. We believe this has inherent limitations around commercial scalability, risk of pathogen transfer, and batch-to-batch variability. We hope to advance the field with DEFINED products which obviate the need for donors /3

VE303 is a potential first-in-class Live Biotherapeutic Product consisting of an 8-strain defined bacterial consortium. "Defined" means the product has a specific, known composition of bacterial strains. Each capsule contains the same strains, at a consistent dose /4

In the Phase 2 CONSORTIUM Study, VE303 demonstrated strong evidence of efficacy and a good safety profile, and so the VE303 high dose has been advanced to Phase 3 development /5

The Phase 3 study, RESTORATiVE303, is now underway in the US. We plan to expand enrollment to include >20 countries. It is a registrational study designed to support a BLA submission /6

We did not have a blueprint for how to get an LBP ready for a registrational study. In the last couple of years, the process development, analytical development, manufacturing, and quality teams @vedantabio worked tirelessly navigating uncharted waters /7

businesswire.com/news/home/2024…

Welcome Christof Marré and Steve Shiff to the Vedanta Biosciences team! businesswire.com/news/home/2024…